Aimmune Therapeutics Inc. said 80 percent of patients being treated with the company’s Palforzia were successfully desensitized to peanut proteins after two years of daily dosing.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
Roche is expecting the U.S. Food and Drug Administration to approve the company’s SMA therapy risdiplam by May 24, 2020, and has suggested plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
BeiGene Ltd. priced the China-based drugmaker’s Brukinsa to treat a rare form of lymphoma at $12,935 for a 30-day supply.
Danish drugmaker Novo Nordisk will offer cheaper insulin to U.S. diabetics in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.
A U.S. group that reviews the value of medicines issued a critical report on Novartis’ Mayzent, calling the new multiple sclerosis drug’s $88,561 list price “far out of line” compared with the product’s benefits for patients.
Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.
EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.
Walgreens Boots Alliance Inc. will pay $269.2 million to settle two whistleblower lawsuits accusing the pharmacy chain of civil fraud for overbilling federal healthcare programs for over a decade.